CO5271676A1 - Metodo para administrar un inhibidor de fosfodiesterasa 4 - Google Patents
Metodo para administrar un inhibidor de fosfodiesterasa 4Info
- Publication number
- CO5271676A1 CO5271676A1 CO00081570A CO00081570A CO5271676A1 CO 5271676 A1 CO5271676 A1 CO 5271676A1 CO 00081570 A CO00081570 A CO 00081570A CO 00081570 A CO00081570 A CO 00081570A CO 5271676 A1 CO5271676 A1 CO 5271676A1
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- formulation
- drug
- compared
- side effects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Un método para aumentar la dosis o la exposición sistémica de una composición inhibidora de la PDE4, comparada con una dosis doble en un momento único, y reducir la gravedad o eliminar la presencia de efectos secundarios, método que comprende: formular una preparación de liberación controlada de dicha composición con un excipiente farmacéuticamente aceptable que pueda formar una composición de liberación controlada que retrase la aparición en el plasma de cantidades detectables de dicha composición cuya velocidad de aumento de concentración plasmática es de un 10% menor si se compara con una formulación de liberación inmediata que contenga igual cantidad de composición y por la misma vía de administración. Un método para reducir o eliminar la aparición de efectos secundarios de una composición inhibidora de la PDE4 que incluye administrar dicha composición en una formulación que produzca una reducción de velocidad en el aumento de su concentración plasmática en un 10% menor si se compara con una formulación de liberación inmediata que contenga igual cantidad de composición y por la misma vía de administración. Un método para reducir la gravedad o eliminar o evitar la aparición de uno o más efectos secundarios de un compuesto que inhibe la PDE4, y dicho método comprende administrar el fármaco en una formulación y/o de una manera que da como resultado un retraso en la aparición en el plasma de cantidades detectables de dicho fármaco, y da como resultado una reducción de la velocidad de aumento en la concentración plasmática de dicho fármaco de al menos aproximadamente 10%, cuando se compara con la de una formulación de liberación inmediata que contiene la misma cantidad de fármaco administrada por la misma vía. <EMI FILE="00081570_1" ID="1" IMF=JPEG >
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16247799P | 1999-10-29 | 1999-10-29 | |
US16264199P | 1999-11-01 | 1999-11-01 | |
US17981700P | 2000-02-02 | 2000-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271676A1 true CO5271676A1 (es) | 2003-04-30 |
Family
ID=27388757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00081570A CO5271676A1 (es) | 1999-10-29 | 2000-10-26 | Metodo para administrar un inhibidor de fosfodiesterasa 4 |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030212112A1 (es) |
EP (1) | EP1225884A4 (es) |
JP (1) | JP2003513038A (es) |
KR (1) | KR20020050249A (es) |
CN (1) | CN1387433A (es) |
AP (1) | AP2002002446A0 (es) |
AR (1) | AR026254A1 (es) |
AU (1) | AU772909B2 (es) |
BG (1) | BG106623A (es) |
BR (1) | BR0015039A (es) |
CA (1) | CA2389293A1 (es) |
CO (1) | CO5271676A1 (es) |
CZ (1) | CZ20021443A3 (es) |
DZ (1) | DZ3249A1 (es) |
EA (1) | EA200200502A1 (es) |
HK (1) | HK1049105A1 (es) |
HU (1) | HUP0203682A3 (es) |
IL (1) | IL148813A0 (es) |
MA (1) | MA25562A1 (es) |
MX (1) | MXPA02004220A (es) |
NO (1) | NO20021937L (es) |
NZ (1) | NZ518002A (es) |
OA (1) | OA12078A (es) |
PE (1) | PE20011004A1 (es) |
PL (1) | PL355262A1 (es) |
SK (1) | SK7292002A3 (es) |
TR (1) | TR200201150T2 (es) |
UY (1) | UY26422A1 (es) |
WO (1) | WO2001032165A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR029984A1 (es) * | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DE10207160A1 (de) * | 2002-02-20 | 2003-12-18 | Altana Pharma Ag | Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff |
AU2003232828B2 (en) * | 2002-05-28 | 2010-06-24 | Takeda Gmbh | Topically applicable pharmaceutical preparation |
US6822114B1 (en) | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
ME00524B (me) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novi postupak za dobijanje roflumilasta |
TW200420554A (en) * | 2003-03-31 | 2004-10-16 | Kyowa Hakko Kogyo Kk | A intra-airway administrating preparation |
US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
JP5383183B2 (ja) | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストを含有する矯味された剤形 |
MX2012006265A (es) * | 2009-12-03 | 2012-07-25 | Opko Health Inc | Formulaciones disacaridas hipersulfatadas. |
CA2861594A1 (en) * | 2011-12-27 | 2013-07-04 | Celgene Corporation | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
CN103536582A (zh) * | 2013-10-12 | 2014-01-29 | 云南龙海天然植物药业有限公司 | 罗氟司特干粉吸入剂 |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684516A (en) * | 1983-08-01 | 1987-08-04 | Alra Laboratories, Inc. | Sustained release tablets and method of making same |
MY121142A (en) * | 1999-02-23 | 2005-12-30 | Smithkline Beecham Corp | Controlled release formulation for treating copd |
AR035987A1 (es) * | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio |
-
2000
- 2000-10-26 WO PCT/US2000/029453 patent/WO2001032165A1/en not_active Application Discontinuation
- 2000-10-26 EA EA200200502A patent/EA200200502A1/ru unknown
- 2000-10-26 OA OA1200200126A patent/OA12078A/en unknown
- 2000-10-26 NZ NZ518002A patent/NZ518002A/en unknown
- 2000-10-26 JP JP2001534370A patent/JP2003513038A/ja not_active Withdrawn
- 2000-10-26 EP EP00975385A patent/EP1225884A4/en not_active Withdrawn
- 2000-10-26 HU HU0203682A patent/HUP0203682A3/hu unknown
- 2000-10-26 CA CA002389293A patent/CA2389293A1/en not_active Abandoned
- 2000-10-26 CZ CZ20021443A patent/CZ20021443A3/cs unknown
- 2000-10-26 PL PL00355262A patent/PL355262A1/xx unknown
- 2000-10-26 DZ DZ003249A patent/DZ3249A1/fr active
- 2000-10-26 CO CO00081570A patent/CO5271676A1/es not_active Application Discontinuation
- 2000-10-26 TR TR2002/01150T patent/TR200201150T2/xx unknown
- 2000-10-26 AR ARP000105644A patent/AR026254A1/es not_active Application Discontinuation
- 2000-10-26 CN CN00815150A patent/CN1387433A/zh active Pending
- 2000-10-26 AP APAP/P/2002/002446A patent/AP2002002446A0/en unknown
- 2000-10-26 SK SK729-2002A patent/SK7292002A3/sk unknown
- 2000-10-26 MX MXPA02004220A patent/MXPA02004220A/es unknown
- 2000-10-26 AU AU13445/01A patent/AU772909B2/en not_active Ceased
- 2000-10-26 KR KR1020027005448A patent/KR20020050249A/ko not_active Application Discontinuation
- 2000-10-26 IL IL14881300A patent/IL148813A0/xx unknown
- 2000-10-26 BR BR0015039-8A patent/BR0015039A/pt not_active IP Right Cessation
- 2000-10-27 PE PE2000001157A patent/PE20011004A1/es not_active Application Discontinuation
- 2000-10-30 UY UY26422A patent/UY26422A1/es not_active Application Discontinuation
-
2002
- 2002-04-17 BG BG106623A patent/BG106623A/bg unknown
- 2002-04-24 NO NO20021937A patent/NO20021937L/no not_active Application Discontinuation
- 2002-04-26 MA MA26618A patent/MA25562A1/fr unknown
- 2002-12-19 HK HK02109231.8A patent/HK1049105A1/zh unknown
-
2003
- 2003-05-02 US US10/429,666 patent/US20030212112A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20011004A1 (es) | 2001-09-28 |
NO20021937L (no) | 2002-05-30 |
TR200201150T2 (tr) | 2002-09-23 |
EP1225884A1 (en) | 2002-07-31 |
IL148813A0 (en) | 2002-09-12 |
OA12078A (en) | 2003-05-28 |
AU1344501A (en) | 2001-05-14 |
NO20021937D0 (no) | 2002-04-24 |
EA200200502A1 (ru) | 2002-10-31 |
AU772909B2 (en) | 2004-05-13 |
CZ20021443A3 (cs) | 2003-01-15 |
BR0015039A (pt) | 2002-06-25 |
HK1049105A1 (zh) | 2003-05-02 |
CA2389293A1 (en) | 2001-05-10 |
UY26422A1 (es) | 2001-07-31 |
BG106623A (bg) | 2003-02-28 |
KR20020050249A (ko) | 2002-06-26 |
HUP0203682A2 (hu) | 2003-04-28 |
JP2003513038A (ja) | 2003-04-08 |
DZ3249A1 (fr) | 2001-05-10 |
SK7292002A3 (en) | 2002-12-03 |
EP1225884A4 (en) | 2005-06-15 |
AP2002002446A0 (en) | 2002-03-31 |
WO2001032165A1 (en) | 2001-05-10 |
CN1387433A (zh) | 2002-12-25 |
HUP0203682A3 (en) | 2003-10-28 |
MA25562A1 (fr) | 2002-10-01 |
PL355262A1 (en) | 2004-04-05 |
NZ518002A (en) | 2004-01-30 |
MXPA02004220A (es) | 2002-10-17 |
AR026254A1 (es) | 2003-02-05 |
US20030212112A1 (en) | 2003-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271676A1 (es) | Metodo para administrar un inhibidor de fosfodiesterasa 4 | |
ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
YU13695A (sh) | Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije | |
RS52149B (sr) | Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona | |
CO5261582A1 (es) | Composiciones de valdecoxib | |
AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
AU2002360462A1 (en) | Compositions containing both sedative and non-sedative antihistamines | |
RS114004A (en) | Modified 2' and 3'-nucleoside produgs for treating flaviridae infections | |
FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
DE69940557D1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
HK1100814A1 (en) | Use of non-sedating barbiturate compounds in preparation of neuroprotective agents | |
CA2447648A1 (en) | Pharmaceutical combinations | |
FR2712807B1 (fr) | Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale . | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
AU619613B2 (en) | Lactamimides in the treatment of drug-resistant protozoal infections | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
ITTO920303A1 (it) | Composizione farmaceutica antiinfiammatoria | |
CO5150233A1 (es) | Formulacion de liberacion controlada para administrar un inhibidor de pde4 | |
ES2091126T3 (es) | Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
KR920019350A (ko) | 자기면역질환요법을 위한 약제조성물 | |
ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |